{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:58:59Z","timestamp":1776347939484,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010390","name":"Saint Louis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jgo.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T18:31:16Z","timestamp":1571941876000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Theodore S.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse W.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen M.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jgo.2019.09.009_bb0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992\u20132013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jgo.2019.09.009_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"issue":"21","key":"10.1016\/j.jgo.2019.09.009_bb0015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"Diehl V. a prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2019.09.009_bb0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jgo.2019.09.009_bb0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2019.09.009_bb0030","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2019.09.009_bb0035","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jgo.2019.09.009_bb0040","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin\u2019s disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jgo.2019.09.009_bb0045","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2010-08-302604","article-title":"Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973\u20132009","volume":"119","author":"Sjoberg","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2019.09.009_bb0050","first-page":"1087","article-title":"Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2019.09.009_bb0055","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jgo.2019.09.009_bb0060","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJM200205023461821","article-title":"Long-term follow-up of Hodgkin\u2019s disease trial","volume":"346","author":"Canellos","year":"2002","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.jgo.2019.09.009_bb0065","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2019.09.009_bb0070","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jgo.2019.09.009_bb0075","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2019.09.009_bb0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jgo.2019.09.009_bb0085","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2017-05-784678","article-title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma","volume":"130","author":"Connors","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.09.009_bb0090","author":"Administration USFaD"},{"issue":"5","key":"10.1016\/j.jgo.2019.09.009_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","article-title":"Bleomycin lung toxicity: who are the patients with increased risk?","volume":"18","author":"Azambuja","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"issue":"35","key":"10.1016\/j.jgo.2019.09.009_bb0100","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group","volume":"31","author":"Boll","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.09.009_bb0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"issue":"10","key":"10.1016\/j.jgo.2019.09.009_bb0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J Clin Epidemiol"},{"issue":"23","key":"10.1016\/j.jgo.2019.09.009_bb0115","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2019.09.009_bb0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"issue":"25","key":"10.1016\/j.jgo.2019.09.009_bb0125","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jgo.2019.09.009_bb0130","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Boll","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jgo.2019.09.009_bb0135","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jgo.2019.09.009_bb0140","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.jgo.2019.09.009_bb0145","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940681930061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940681930061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:50:03Z","timestamp":1761817803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940681930061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S187940681930061X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2019.09.009","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}